MYC and cancer: Moreover, gene set enrichment analysis (GSEA) comparing iCMS2 and iCMS3 in our dataset aligned with previous findings (Joanito et al., 2022), demonstrating that MYC activity was mainly upregulated in iCMS2 cancer cells, whereas epithelial-mesenchymal transition (EMT) and TGF-beta signaling were enriched in iCMS3 cancer cells (Fig. S7C).